Andersen, G. T., Ianevski, A., Resell, M., Pojskic, N., Rabben, H.-L., Geithus, S., Kodama, Y., Hiroyuki, T., Kainov, D., Grønbech, J. E., Hayakawa, Y., Wang, T. C., Zhao, C.-M., & Chen, D. (2024). Multi-bioinformatics revealed potential biomarkers and repurposed drugs for gastric adenocarcinoma-related gastric intestinal metaplasia. Npj Systems Biology and Applications, 10(1). https://doi.org/10.1038/s41540-024-00455-0

Su, S. H., Mitani, Y., Li, T., Sachdeva, U., Flashner, S., Klein-Szanto, A., Dunbar, K. J., Abrams, J., Nakagawa, H., & Gabre, J. (2024). Lactate Suppresses Growth of Esophageal Adenocarcinoma Patient-Derived Organoids through Alterations in Tumor NADH/NAD+ Redox State. Biomolecules, 14(9), 1195. https://doi.org/10.3390/biom14091195

Ng, A. W. T., McClurg, D. P., Wesley, B., Zamani, S. A., Black, E., Miremadi, A., Giger, O., Hoopen, R. ten, Devonshire, G., Redmond, A. M., Grehan, N., Jammula, S., Blasko, A., Li, X., Aparicio, S., Tavaré, S., Edwards, P. A. W., Grehan, N., … Fitzgerald, R. C. (2024). Disentangling oncogenic amplicons in esophageal adenocarcinoma. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47619-4

Jamison, J. K., May, M. S., Raufi, A. G., Luk, L., Wong, W., Mundi, P. S., & Manji, G. A. (2024). A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. The Oncologist, 29(4), 350–355. https://doi.org/10.1093/oncolo/oyad315

Bolshinsky, V., Sweet, D. E., Vitello, D. J., Jia, X., Holubar, S. D., Church, J., Herts, B. R., & Steele, S. R. (2024). Using CT-Based Pelvimetry and Visceral Obesity Measurements to Predict Total Mesorectal Excision Quality for Patients Undergoing Rectal Cancer Surgery. Diseases of the Colon & Rectum, 67(7), 929–939. https://doi.org/10.1097/dcr.0000000000003147

Ben-Ami, R., Wang, Q.-L., Zhang, J., Supplee, J. G., Fahrmann, J. F., Lehmann-Werman, R., Brais, L. K., Nowak, J., Yuan, C., Loftus, M., Babic, A., Irajizad, E., Davidi, T., Zick, A., Hubert, A., Neiman, D., Piyanzin, S., Gal-Rosenberg, O., Horn, A., … Wolpin, B. M. (2023). Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut, gutjnl-2023-331074. https://doi.org/10.1136/gutjnl-2023-331074

Solfisburg, Q. S., Baldini, F., Baldwin-Hunter, B., Austin, G. I., Lee, H. H., Park, H., Freedberg, D. E., Lightdale, C. J., Korem, T., & Abrams, J. A. (2023). The Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett’s Esophagus and High-Grade Dysplasia or Adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention, 33(3), 371–380. https://doi.org/10.1158/1055-9965.epi-23-0652

Weh, K. M., Howard, C. L., Zhang, Y., Tripp, B. A., Clarke, J. L., Howell, A. B., Rubenstein, J. H., Abrams, J. A., Westerhoff, M., & Kresty, L. A. (2024). Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. JCI Insight. https://doi.org/10.1172/jci.insight.168112

Sun, J., Sepulveda, J. L., Komissarova, E. V., Hills, C., Seckar, T. D., LeFevre, N. M., Simonyan, H., Young, C., Su, G., Del Portillo, A., Wang, T. C., & Sepulveda, A. R. (2024). CDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett’s-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions. Cellular and Molecular Gastroenterology and Hepatology, 17(5), 769–784. https://doi.org/10.1016/j.jcmgh.2024.01.014

Yoon, J. Y., Lim, F., Shah, S. C., Rubenstein, J. H., Abrams, J. A., Katzka, D., Inadomi, J., Kim, M. K., & Hur, C. (2024). Endoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis. American Journal of Gastroenterology, 119(7), 1289–1297. https://doi.org/10.14309/ajg.0000000000002672

Dunbar, K. J., Wong, K. K., & Rustgi, A. K. (2024). Cancer-Associated Fibroblasts in Esophageal Cancer. Cellular and Molecular Gastroenterology and Hepatology, 17(5), 687–695. https://doi.org/10.1016/j.jcmgh.2024.01.008

Wu, S. P., Keshavjee, S. H., Yoon, S. S., & Kwon, S. (2023). Survival Outcomes and Patterns of Care for Stage II or III Resected Gastric Cancer by Race and Ethnicity. JAMA Network Open, 6(12), e2349026. https://doi.org/10.1001/jamanetworkopen.2023.49026

Lu, H., Cao, L. L., Ballout, F., Belkhiri, A., Peng, D., Chen, L., Chen, Z., Soutto, M., Wang, T. C., Que, J., Giordano, S., Washington, M. K., Chen, S., McDonald, O. G., Zaika, A., & El-Rifai, W. (2023). Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma. Gut, 73(1), 47–62. https://doi.org/10.1136/gutjnl-2023-329455

Manji, G. A., Lee, S., Del Portillo, A., May, M., Ana, S. S., Alouani, E., Sender, N., Negri, T., Gautier, K., Ge, L., Fan, W., Xie, M., Sethi, A., Schrope, B., Tan, A. C., Park, H., Oberstein, P. E., Shah, M. A., & Raufi, A. G. (2023). Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma. JAMA Oncology, 9(12), 1702. https://doi.org/10.1001/jamaoncol.2023.4423

Muthupalani, S., Annamalai, D., Feng, Y., Ganesan, S. M., Ge, Z., Whary, M. T., Nakagawa, H., Rustgi, A. K., Wang, T. C., & Fox, J. G. (2023). IL-1β transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-39907-8

Cruz-Acuña, R., Kariuki, S. W., Sugiura, K., Karaiskos, S., Plaster, E. M., Loebel, C., Efe, G., Karakasheva, T., Gabre, J. T., Hu, J., Burdick, J. A., & Rustgi, A. K. (2023). Engineered hydrogel reveals contribution of matrix mechanics to esophageal adenocarcinoma and identifies matrix-activated therapeutic targets. Journal of Clinical Investigation, 133(23). https://doi.org/10.1172/jci168146

Rustgi, S. D., McKinley, M., McBay, B., Zylberberg, H. M., Gomez, S. L., Hur, C., Kastrinos, F., Gupta, S., Kim, M. K., Itzkowitz, S. H., & Shah, S. C. (2023). Epidemiology of Gastric Malignancies 2000–2018 According to Histology: A Population-Based Analysis of Incidence and Temporal Trends. Clinical Gastroenterology and Hepatology, 21(13), 3285-3295.e8. https://doi.org/10.1016/j.cgh.2023.01.037

LaRose, M., Manji, G. A., & Bates, S. E. (2024). Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer. Seminars in Oncology, 51(1–2), 36–44. https://doi.org/10.1053/j.seminoncol.2023.11.001

Chandar, A. K., Keerthy, K., Gupta, R., Grady, W. M., Canto, M. I., Shaheen, N. J., Thota, P. N., Iyer, P. G., Wang, J. S., Falk, G. W., Abrams, J. A., Dumot, J., Faulx, A., Markowitz, S. D., Willis, J., Moinova, H., Guda, K., Brock, W., & Chak, A. (2023). Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study. American Journal of Gastroenterology, 119(5), 823–829. https://doi.org/10.14309/ajg.0000000000002593

Lee, M., Thomas, A. S., Lee, S. Y., Cho, Y. J., Jung, H.-S., Yun, W.-G., Han, Y., Jang, J.-Y., Kluger, M. D., & Kwon, W. (2023). Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer Database. Journal of Gastrointestinal Surgery, 27(11), 2484–2492. https://doi.org/10.1007/s11605-023-05850-2

Cytryn, S. L., Moy, R. H., Cowzer, D., Shah, R. H., Chou, J. F., Joshi, S. S., Ku, G. Y., Maron, S. B., Desai, A., Yang, J., Sugarman, R., Rao, D., Goldberg, Z., Charalambous, C., Lapshina, M., Antoine, A., Socolow, F., Trivedi, N., Capanu, M., … Janjigian, Y. Y. (2023). First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. The Lancet Oncology, 24(10), 1073–1082. https://doi.org/10.1016/s1470-2045(23)00358-3

Crowe, B. R., Krigel, A., Li, T., Haile, R., Al-Ani, F., Lebwohl, B., Abrams, J. A., & Araujo, J. L. (2023). Veterans with multiple risk factors for Barrett’s esophagus are infrequently evaluated with upper endoscopy. Diseases of the Esophagus, 36(9). https://doi.org/10.1093/dote/doad007

Emilsson, L., Maret-Ouda, J., & Ludvigsson, J. F. (2023). Mortality in small bowel cancers and adenomas – A nationwide, population-based matched cohort study. Cancer Epidemiology, 85, 102399. https://doi.org/10.1016/j.canep.2023.102399

Rubenstein, J. H., Burns, J. A., Arasim, M. E., Firsht, E. M., Harbrecht, M., Widerquist, M., Evans, R. R., Inadomi, J. M., Chang, J. W., Hazelton, W. D., Hur, C., Kurlander, J. E., Lim, F., Luebeck, G., Macdonald, P. W., Reddy, C. A., Saini, S. D., Tan, S. X., Waljee, A. K., & Lansdorp-Vogelaar, I. (2023). Yield of Repeat Endoscopy for Barrett’s Esophagus After Normal Index Endoscopy. American Journal of Gastroenterology, 118(7), 1168–1174. https://doi.org/10.14309/ajg.0000000000002204

Ko, A. H., Kim, K.-P., Siveke, J. T., Lopez, C. D., Lacy, J., O’Reilly, E. M., Macarulla, T., Manji, G. A., Lee, J., Ajani, J., Alsina Maqueda, M., Rha, S.-Y., Lau, J., Al-Sakaff, N., Allen, S., Lu, D., Shemesh, C. S., Gan, X., Cha, E., & Oh, D.-Y. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist, 28(6), 553-e472. https://doi.org/10.1093/oncolo/oyad022

Furey, K. B., Anderson, Z. S., Kuznicki, M. L., Klar, M., Roman, L. D., Wright, J. D., & Matsuo, K. (2023). Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer. Gynecologic Oncology, 173, 122–129. https://doi.org/10.1016/j.ygyno.2023.04.025

Quante, M., Wang, T. C., & Bass, A. J. (2022). Adenocarcinoma of the oesophagus: is it gastric cancer? Gut, 72(6), 1027–1029. https://doi.org/10.1136/gutjnl-2022-327096

Shah, M. A., Altorki, N., Patel, P., Harrison, S., Bass, A., & Abrams, J. A. (2023). Improving outcomes in patients with oesophageal cancer. Nature Reviews Clinical Oncology, 20(6), 390–407. https://doi.org/10.1038/s41571-023-00757-y

Yoon, C., Lu, J., Kim, B.-J., Cho, S.-J., Kim, J. H., Moy, R. H., Ryeom, S. W., & Yoon, S. S. (2023). Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy. Journal of Gastrointestinal Surgery, 27(4), 666–676. https://doi.org/10.1007/s11605-022-05568-7

Guo, C., Figueiredo, I., Gurel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J., Bogdan, D., Gallagher, L., Sharp, A., Fenor de la Maza, M. D., Rescigno, P., Westaby, D., Chandran, K., Riisnaes, R., Ferreira, A., … de Bono, J. S. (2023). B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology, 83(3), 224–238. https://doi.org/10.1016/j.eururo.2022.09.004

Chen, L., Lu, H., Peng, D., Cao, L. L., Ballout, F., Srirmajayam, K., Chen, Z., Bhat, A., Wang, T. C., Capobianco, A., Que, J., McDonald, O. G., Zaika, A., Zhang, S., & El-Rifai, W. (2022). Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma. Gut, 72(3), 421–432. https://doi.org/10.1136/gutjnl-2022-327076

Filip, I., Wang, A., Kravets, O., Orenbuch, R., Zhao, J., Perea-Chamblee, T. E., Manji, G. A., López de Maturana, E., Malats, N., Olive, K. P., & Rabadan, R. (2023). Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Medicine, 15(1). https://doi.org/10.1186/s13073-023-01154-x

Yeh, C., Zhou, M., Sigel, K., Jameson, G., White, R., Safyan, R., Saenger, Y., Hecht, E., Chabot, J., Schreibman, S., Juzyna, B., Ychou, M., Conroy, T., Fojo, T., Manji, G. A., Von Hoff, D., & Bates, S. E. (2022). Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 28(2), 139–148. https://doi.org/10.1093/oncolo/oyac217

Ballout, F., Lu, H., Chen, L., Sriramajayam, K., Que, J., Meng, Z., Wang, T. C., Giordano, S., Zaika, A., McDonald, O., Peng, D., & El-Rifai, W. (2022). APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett’s-associated esophageal adenocarcinomas. Journal of Experimental & Clinical Cancer Research, 41(1). https://doi.org/10.1186/s13046-022-02472-5

Besharati, S., Liu‐Jarin, X., Chen, X., & Cimic, A. (2022). An unusual case of carcinoma with mesonephric‐like features with a spindle cell component diagnosed on the Pap test of the uterine cervix: Cytomorphologic and immunophenotypic features and diagnostic pitfalls. Diagnostic Cytopathology, 50(11). Portico. https://doi.org/10.1002/dc.25009

Lee, M., Kudose, S., Del Portillo, A., Ko, H. M., Lee, H., Pittman, M. E., Salomao, M. A., Sepulveda, A. R., & Lagana, S. M. (2021). Invasive carcinoma versus pseudoinvasion: interobserver variability in the assessment of left-sided colorectal polypectomies. Journal of Clinical Pathology, 75(9), 593–597. https://doi.org/10.1136/jclinpath-2021-207406

Bailey, S., Wang, Q., Kong, C. Y., Stone, K., Veluswamy, R., Bates, S. E., Smith, C. B., Wisnivesky, J. P., & Sigel, K. (2022). Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. Current Problems in Cancer, 46(4), 100867. https://doi.org/10.1016/j.currproblcancer.2022.100867

Kang, S., Park, M., Cho, J. Y., Ahn, S. jin, Yoon, C., Kim, S. G., & Cho, S.-J. (2022). Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma. Gastric Cancer, 25(4), 678–696. https://doi.org/10.1007/s10120-022-01290-0

Rubenstein, J. H., Omidvari, A.-H., Lauren, B. N., Hazelton, W. D., Lim, F., Tan, S. X., Kong, C. Y., Lee, M., Ali, A., Hur, C., Inadomi, J. M., Luebeck, G., & Lansdorp-Vogelaar, I. (2022). Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 163(1), 163–173. https://doi.org/10.1053/j.gastro.2022.03.037

Ekheden, I., Ludvigsson, J. F., Yin, L., Elbe, P., & Ye, W. (2022). Esophageal abnormalities and the risk for gastroesophageal cancers—a histopathology-register-based study in Sweden. European Journal of Epidemiology, 37(4), 401–411. https://doi.org/10.1007/s10654-021-00833-6

Troy, C., Gill, B. J. A., Miller, M. L., Hickman, R. A., Canoll, P., Zacharoulis, S., Feldstein, N. A., & Bruce, J. N. (2022). Adenocarcinoma Arising in a Yolk Sac Tumor of the Pineal Gland. Journal of Neuropathology & Experimental Neurology, 81(4), 291–295. https://doi.org/10.1093/jnen/nlac002

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., Won, E., Kelsen, D. P., Ilson, D. H., Janjigian, Y. Y., Capanu, M., & Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 89(2), 255–265. https://doi.org/10.1007/s00280-021-04384-1

Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x